| Similar Articles |
|---|
 |
The Motley Fool
October 6, 2010
Jeremy Phillips |
Reasons to Sell Sequenom Today Over the past 12 months, Sequenom has risen 115.7% versus an S&P 500 return of 11.3%. Investors in Sequenom have every reason to be proud of their returns.   |
The Motley Fool
October 9, 2010
Jeremy Phillips |
Should You Sell Best Buy Right Now? Best Buy has failed four of these quick tests that would make it a sell. |
The Motley Fool
April 18, 2011
Jeremy Phillips |
Time to Sell Force Protection? Today I'm laser-focused on Force Protection, ready to evaluate its price, valuation, margins, and liquidity. Let's get started! |
The Motley Fool
August 16, 2011
Jeremy Phillips |
Time to Sell Advanced Battery Technologies? I'm laser-focused on Advanced Battery Technologies, ready to evaluate its price, valuation, margins, and liquidity. |
The Motley Fool
November 30, 2010
Jeremy Phillips |
Time to Sell Motorola? Investors in Motorola are no doubt disappointed with their returns, but is now the time to cut and run? |
The Motley Fool
October 8, 2010
Jeremy Phillips |
Should You Sell Energy Conversion Devices Right Now? We're seeking danger signs among this beloved stock. |
The Motley Fool
October 7, 2010
Jeremy Phillips |
Should You Sell Advanced Battery Technologies Right Now? We're seeking danger signs among Fools' most beloved stocks. |
The Motley Fool
October 5, 2010
Jeremy Phillips |
Should You Sell E*TRADE Financial Right Now? We're seeking danger signs among our most beloved stocks. |
The Motley Fool
October 16, 2010
Jeremy Phillips |
Time to Sell Progress Energy? Let's focus on Progress Energy and evaluate its price, valuation, margins, and liquidity to search for danger signs. |
The Motley Fool
February 18, 2009
Tim Beyers |
Stocks the Rich Executives Are Buying Sometimes insiders are buying for all the right reasons. Who's at it this week?: Seagate Technology... Prospect Capital... Interactive Intelligence... Sequenom... 99 Cents Only Stores... |
The Motley Fool
October 18, 2011
Brian Orelli |
How Not to Gain 75% of Your Company's Value Overnight A 75% increase in price certainly seems possible, but not until investors are convinced that Sequenom can execute on its sales plan the way it has on its clinical plan. |
The Motley Fool
June 27, 2008
Brian Orelli |
The Right Time to Raise Capital After seeing its stock double in less than a month, thanks to some stellar preliminary results from its prenatal Down syndrome test, diagnostic-test maker Sequenom figured now was a perfect time to get some money into the coffers. |
The Motley Fool
May 18, 2009 |
2 Stocks Hitting Low Notes These stocks have hit bottom. Are they ready to bounce? Take a look at: Sequenom, Inc. ... ULTRASHORT MSCI Emerging Markets... |
The Motley Fool
September 18, 2009
Brian Orelli |
Hey, Sequenom, That's Great, But ... Investors are still waiting for some real second-quarter news from Sequenom. |
The Motley Fool
July 12, 2011
Brian Orelli |
Ducks in Order; Now Let's See Some Data Sequenom is getting all its ducks in a row in preparation for launching its SensiGene Trisomy 21 laboratory-developed test. |
The Motley Fool
August 15, 2011
Brian Orelli |
Another Partner, but Still No Data Sequenom signs up a European partner. |
The Motley Fool
April 30, 2009 |
3 Stocks Hitting Low Notes These stocks have hit bottom. Are they ready to bounce? |
The Motley Fool
June 5, 2008
Brian Orelli |
Test Results Boost Sequenom's Stock They are early results, but the Down syndrome tests could bring big changes to the industry. |
The Motley Fool
January 30, 2009
Brian Orelli |
Sequenom Is a Rule Breaker Sequenom has potential; it wants to become the go-to place for molecular diagnostics. |
The Motley Fool
September 24, 2008
Brian Orelli |
100% Results From Sequenom The company presents more data on its molecular diagnostic and buys a lab to run the tests in. |
The Motley Fool
May 9, 2011
Brian Orelli |
Why Is Sequenom Up 20%? Investors appear to be overreacting. |
The Motley Fool
May 8, 2010 |
Sequenom Restarting Development of Diagnostic Test for Down Syndrome The latest news at the San Diego-based biotech. |
